The novel protein kinase C epsilon isoform modulates acetylcholine release in the rat neuromuscular junction by Teresa Obis et al.
RESEARCH Open Access
The novel protein kinase C epsilon isoform
modulates acetylcholine release in the rat
neuromuscular junction
Teresa Obis, Erica Hurtado, Laura Nadal, Marta Tomàs, Mercedes Priego, Anna Simon, Neus Garcia†,
Manel M. Santafe†, Maria A. Lanuza*† and Josep Tomàs*†
Abstract
Background: Various protein kinase C (PKC) isoforms contribute to the phosphorylating activity that modulates
neurotransmitter release. In previous studies we showed that nPKCε is confined in the presynaptic site of the
neuromuscular junction and its presynaptic function is activity-dependent. Furthermore, nPKCε regulates phorbol
ester-induced acetylcholine release potentiation, which further indicates that nPKCε is involved in
neurotransmission. The present study is designed to examine the nPKCε involvement in transmitter release at the
neuromuscular junction.
Results: We use the specific nPKCε translocation inhibitor peptide εV1-2 and electrophysiological experiments to
investigate the involvement of this isoform in acetylcholine release. We observed that nPKCε membrane translocation
is key to the synaptic potentiation of NMJ, being involved in several conditions that upregulate PKC isoforms coupling
to acetylcholine (ACh) release (incubation with high Ca2+, stimulation with phorbol esters and protein kinase A,
stimulation with adenosine 3′,5′-cyclic monophosphorothioate, 8-Bromo-, Rp-isomer, sodium salt -Sp-8-BrcAMP-). In all
these conditions, preincubation with the nPKCε translocation inhibitor peptide (εV1-2) impairs PKC coupling to
acetylcholine release potentiation. In addition, the inhibition of nPKCε translocation and therefore its activity
impedes that presynaptic muscarinic autoreceptors and adenosine autoreceptors modulate transmitter
secretion.
Conclusions: Together, these results point to the importance of nPKCε isoform in the control of acetylcholine
release in the neuromuscular junction.
Keywords: PKC epsilon, Neuromuscular junction, Neurotransmission, Acetylcholine release, Electrical
stimulation, Protein kinase C, Protein kinase A, Ca2+, Muscarinic receptors, Adenosine receptors
Background
Protein kinase C (PKC) regulates many neuronal func-
tions, including ion channel activity, neurotransmitter
release, membrane receptor operation and cell differen-
tiation. The PKC family can be classified into three
groups on the basis of their biochemical properties:
conventional PKCs (cPKCs α, βI and βII), novel PKCs
(nPKCs δ, ε, η and θ) and atypical PKCs (aPKCs ζ and
ι/λ). These isoforms have distinct tissue and cell
distributions [1, 2]. Intracellular PKC-binding proteins
(RACKs, for receptors for activated C-kinase) achieve
the specific patterns of distribution and bring activated
PKC isoforms closer to their endogenous protein sub-
strates [3, 4].
Presynaptic protein phosphorylation by the PKC family
is an important mechanism that regulates transmitter re-
lease [5–9]. In the paradigmatic neuromuscular junction
(NMJ), whereas protein kinase A (PKA) is tonically
coupled to potentiate ACh release, PKC couples in a
regulated manner when several activity demands are
imposed [9–12]. The fine regulation of neurotransmis-
sion in the motor nerve terminals is modulated by
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presynaptic muscarinic acetylcholine autoreceptors
(mAChR) [10, 13–18], adenosine receptors (AR) [19–21]
and neurotrophin receptors (NR) [22–25]. Furthermore,
the way that a synapse works is largely the logical out-
come of the confluence of these metabotropic signaling
pathways on PKC [2, 5–8]. Therefore, it is important to
know which is the PKC isoform (or isoforms) that regu-
lates acetylcholine (ACh) release in the NMJ.
Protein kinase C epsilon (nPKCε), a novel PKC iso-
form, is involved in regulating various cellular functions.
It is highly expressed in the brain and several neural
functions of nPKCε, including neurotransmitter release,
have been identified [26]. nPKCε is also present in the
skeletal muscle [27, 28] and it has recently been reported
that nPKCε is exclusively located at the nerve terminals
on the NMJ, is regulated by synaptic activity and is in-
volved in phorbol-ester induced ACh release potenti-
ation at the NMJ [29]. However, to date, no information
is available about how the presynaptic nPKCε regulates
transmitter release.
In the present study, we focused on nPKCε involvement
in transmitter release. We disrupted the interaction
between nPKCε and its specific RACK and therefore its
activation) with an isozyme-selective translocation peptide
inhibitor (εV1-2) in acute electrophysiological experi-
ments in the adult NMJ. We observed that the nPKCε
played a key role in several conditions involving PKC iso-
forms coupling to ACh release potentiation (for instance,
incubation with phorbol 12-myristate 13-acetate –PMA-,
increased Ca2+ inflow and PKA stimulation with Sp-8-
BrcAMP -Adenosine 3′,5′-cyclic Monophosphorothioate,
8-Bromo-, Rp-Isomer, Sodium Salt-). In all these condi-
tions, preincubation with the translocation inhibitor εV1-
2 impairs PKC coupling to release potentiation. We also
found that interference with nPKCε translocation and ac-
tivity impedes the well known functional operation of the
mAChR and AR in the control of transmitter secretion.
We conclude that nPKCε is an essential element that
modulates ACh release in the NMJ.
Results
Inhibition of nPKCε by the peptide εV1-2 in basal
conditions
To inhibit the nPKCε activity we used an isozyme-
selective translocation peptide inhibitor (εV1-2; [30, 31])
derived from the C2 domain of the nPKCε. It binds to
the anchoring protein εRACK (β’COP) and disrupts the
interaction between nPKCε and its specific εRACK inhi-
biting thus, its translocation to the membrane and so its
activation. Western blot analysis was carried out to
determine the presence of the nPKCε isoform in rat dia-
phragm skeletal muscle. Synaptic membranes were ob-
tained as previously described [12, 27]. Fig. 1a (left and
right) shows that incubation with the εV1-2 peptide
(100 μM) results in a rapid (10 min) and considerable
decrease in nPKCε (70 %) and phosphorilated protein
kinase C epsilon (pnPKCε) (40 %) in the synaptic mem-
brane. This initial reduction is maintained after at least
60 min of incubation with the inhibitor peptide. These
changes in the level of nPKCε and pnPKCε induced by
incubation with εV1-2 confirm that the peptide affects
nPKCε levels. Furthermore, both, the nPKCε phosphor-
ylation and its translocation to the membrane are indica-
tive of nPKCε activation. Therefore, the decrease in
pnPKCε in the synaptic membrane fraction indicates a
less amount of active nPKCε and also indicates that the
peptide is correctly acting to inhibit the action of this
isoform. No change was observed in the expression of
the nPKCε and pnPKCε in the presence of 100 μM of
the scrambled peptide (not shown). Fig. 1b1 shows
semithin cross-sections from whole-mount multiple-
immunofluorescent stained levator auris longus mus-
cles (LAL) [32] that demonstrate that nPKCε is
exclusively located at the nerve terminal of the NMJ.
The image shows a nPKCε fine granular green im-
munofluorescence located over the postsynaptic line
of the nicotinic acetylcholine receptor (nAChR) site
(in red) and externally surrounded by the Schwann
cell (S-100, in blue). This green zone corresponds to
the syntaxin (Synt) labeled axonal buttons of the
nerve terminal (B2). These results all suggest that the
nPKCε isoform is tonically involved in some nerve
terminal mechanism because nPKCε is exclusively lo-
calized in the presynaptic component at the NMJ.
To determine whether nPKCε is constitutively
involved in the mechanism of ACh release in resting
NMJs, we performed electrophysiological experiments in
muscles incubated with εV1-2 and carried out a
concentration-dependence analysis in the range of
doses commonly used in a variety of cells and models
(1–100 μM, 1 h incubation). Fig. 1c shows that the
different concentrations used changed neither the
quantal content of the evoked endplate potentials
(EPP) nor the size or frequency of the miniature end-
plate potentials (MEPPs) (in all cases p > 0.05). Raw
data of the MEPPs (right) and EPPs (left) in the pres-
ence and absence of εV1-2 (100 μM) are shown in
Fig. 1d. We also performed some experiments with
εV1-2 (10–100 μM) for 3 h which had no effect on
ACh release (percentage of change in the quantal
content: 4.14 % ± 1.56; p > 0.05). Moreover, preincuba-
tion with εV1-2 does not change the normal depres-
sion of the EPPs (about a 50 % reduction in size)
observed at 40Hz after two minutes of continuous
stimulation (data not shown). Thus, the results show
that there is a lack of tonic coupling to transmitter
release of nPKCε in basal conditions. This result is in
accordance with the well established lack of effect in
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basal conditions of the PKC paninhibitor Calphostin
C (CaC) which acts on the regulatory domain (C1) of
all PKC isoforms (Fig. 1e and also [9]). These results
demonstrate that in resting muscles which do not
receive action potentials from the motor neuron
soma, neither PKC nor nPKCε are coupled to regu-
late ACh release.
However, we observed that in basal conditions, nPKCε
inhibition with εV1-2 fully inhibited the well established
PMA-induced pharmacologic potentiation of ACh re-
lease (Fig. 1f and also [29] indicating that nPKCε plays a
role in neurotransmission at the NMJ. Therefore, it
seems that although nPKCε is not involved in neuro-
transmission in basal conditions, this isoform plays a key
role in regulating ACh release when PKC family is stim-
ulated by PMA and coupled to the neurotransmission
mechanism. In previous studies, we found several other
conditions in which PKC is coupled to enhance evoked
neurotransmitter release. In particular, quantal content
was effectively reduced by CaC incubation (indicating
the regulated coupling of PKC isoforms to ACh release)
in several conditions with enhanced neurotransmission
Fig. 1 nPKCε in NMJ. a Western blot analysis of nPKCε and pnPKCε in the synaptic membrane of diaphragm muscles in the control and after
incubation with the inhibitor peptide εV1-2 (100 μM). Western blot is shown at the left and quantitation at the right. b Immunohistochemistry in
semithin sections from a whole-mount multiple-immunofluorescent stained LAL muscle. nPKCε isoform immunolabaled in green, AChRs in red,
and the Schwann cell (S-100, in B1) or syntaxin (Synt, in B2) in blue. c Quantal content, MEPP frequency and MEPP amplitude in basal conditions
and after 1 h of incubation with εV1-2 at concentrations of 1–100 μM. d Intracellular recordings show evoked EPPs and spontaneous MEPPs in
basal conditions and after incubation with εV1-2. Examples of EPPs (left, horizontal bar 4 ms, vertical bar 5mv) and MEPPs (right, horizontal bar
20 ms, vertical bar 0.5mv) superimposed raw data. e Intracellular recordings show evoked EPPs in basal conditions and after incubation with CaC
(horizontal bar 4 ms, vertical bar 5mv). f Raw data shows the effects of PMA in basal conditions and after incubation with εV1-2 on ACh release
(horizontal bars 4 ms; vertical bars, left 10 mV, right 5 mV)
Obis et al. Molecular Brain  (2015) 8:80 Page 3 of 16
such as high Ca2+ media, electrical stimulation (continu-
ous at 1Hz), PKA stimulation (with Sp-8-BrcAMP) or
mAChR block or imbalance (for instance with atropine
–AT–) [9–12]. Therefore, we decided to investigate the
possible involvement of nPKCε in the PKC isoforms
coupling to the release in these conditions.
nPKCε in high Ca2+ and during continuous electrical
stimulation
The isoform nPKCε is a novel PKC activated by diacyl-
glycerol but not by Ca2+. Only classical PKC isoforms
are activated by Ca2+. However, changes in external Ca2+
concentration and Ca2+ inflow at nerve terminals
through voltage-dependent calcium channels (VDCC)
lead to changes in ACh release. Fig. 2a shows increased
quantal content in high Ca2+ (5 mM) and decreased
quantal content in high Mg2+ (5 mM) or after the P/Q-
type VDCC block with ω-Agatoxin-IVA (ω-Aga-IVA;
100 nM). The figure also shows that the increased
release in high Ca2+ can be partly mediated by PKC acti-
vation because it is reduced by CaC whereas CaC has no
effect on the low Ca2+ entry and low release conditions
produced in high Mg2+ or in the presence of the P/Q-
type VDCC blocker ω-Aga-IVA.
Quantal content was also reduced by CaC incubation
when neurotransmission was maintained in the neuro-
muscular preparation by constant electrical stimulation
at 1 Hz (Fig. 2b). Although there is no change in quantal
content at this stimulation rate (no facilitation or
depression), the effect of CaC indicates the coupling of
some PKC isoforms to maintain ACh release during ac-
tivity. The shadowed columns in Fig. 2b compare the
similar effects of CaC at high Ca2+ concentrations and
during continuous activity imposed at 1 Hz, two of the
conditions in which PKC family is coupled to ACh re-
lease. Here we tried to know whether nPKCε plays a role
controlling the involvement of other PKC isoforms in
ACh release in these conditions.
Although nPKCε is Ca2+ independent, we performed
experiments in high Ca2+ and during stimulation at
1 Hz to evaluate a possible involvement of nPKCε in the
coupling of PKCs to transmitter release in these condi-
tions. After a preincubation (1 h) with high Ca2+
(5 mM), or after a similar period of continuous
Fig. 2 Effect of εV1-2 in high Ca2+ or PMA medium and during
electrical stimulation on transmitter release in diaphragm muscle. a
Histogram shows the effect of high Ca2+ (5 mM), high magnesium
(5 mM) and the P/Q-type channel blocker ω-Agatoxin-IVA (100 nM)
on the evoked transmitter release in basal conditions and after CaC
incubation (2: CaC; 10 μM). The histogram in (b) compares the effect
of CaC or εV1-2 in high Ca2+ medium and during continuous electrical
stimulation (1Hz, 1 h) on the transmitter release. Diaphragm muscles
were preincubated (1 h) with high Ca2+ (5 mM; 1: Ca2+) and then
evaluated the effect of εV1-2 (10 μM, 1 h of incubation; 2: εV1-2). We
also evaluated the εV1-2 effect during electrical stimulation at 1 Hz
(1: 1 Hz, 2: εV1-2). To evaluate the effect of the unspecific blocker CaC
when the peptide εV1-2 is present, we performed a pretreatment with
εV1-2 and a second incubation with CaC (10 μM, an additional
hour; 2: CaC). This was done in conditions of both high Ca2+ (10 μM,
1 h of incubation, 1: εV1-2, Ca2+) and continuous electrical stimulation
(1: εV1-2, 1Hz). c Changes in ACh release after PMA (10 nM) and PMA
in presence of continuous electrical stimulation (PMA, 1 Hz, 1 h). We
also evaluated the changes in ACh release when a PMA or a CaC
(10 μM) preincubated muscle was then incubated with the other drug
(1: CaC, 2: PMA; 1: PMA, 2: CaC). To determine whether nPKCε affects
the PMA-induced enhancing of neurotransmission, we preincubated
the neuromuscular preparation (1 h) with the εV1-2 peptide (1: εV1-2,
1 μM, 10 μM, 100 μM) and then evaluated the effect of PMA (2: PMA).
We also studied the link between electrical stimulation and PMA
effects in presence of electrical stimulation at 1Hz (1: εV1-2, 10 μM,
1 Hz; 2: PMA). * p < 0.05 vs. the corresponding control
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stimulation, we evaluated the effect of εV1-2 (10 μM, 1
additional hour of incubation). We found no change in
quantal content (Fig. 2b). These results suggest that
nPKCε may not be directly related to ACh release and
that CaC in high Ca2+ or during activity may inhibit
another PKC isoform coupled to release. However, we
also performed a pretreatment with εV1-2 (10 μM, 1 h
of incubation) and a second incubation with CaC
(10 μM, an additional hour). We worked in high Ca2+
media and with continuous electrical stimulation at
1 Hz. The last two columns in Fig. 2b show that, in
these two conditions, CaC cannot reduce ACh release,
as expected. Therefore, it seems that the effect of high
Ca2+ and electrical activity on PKC isoforms coupling to
release cannot be reversed by blocking nPKCε but can
be prevented by previous nPKCε block. These results in-
dicate the involvement of nPKCε in transmitter release
by regulating the coupling of other/s PKC isoform/s,
and suggest that once nPKCε has been recruited by the
ACh release mechanism (in the presence of high Ca2+ or
during the continuous electrical stimulation processes),
a long-lasting function in the membrane may make the
kinase competent for some time. Thus, new transloca-
tion and activation may be unnecessary.
nPKCε in phorbol ester-induced ACh release
As showed above in Fig. 1f, evoked ACh release was
strongly stimulated by PMA and this effect of PMA can
be prevented by preincubation with CaC, which acts on
the same domain of PKCs (C1) as PMA (Fig. 2c). How-
ever, CaC cannot reverse the effect of PMA, which indi-
cates the potency of PMA as a positive pharmacological
regulator of PKC activity. Figure 2c also shows that
PMA does not need to coincide with electrical stimula-
tion to potentiate release by about 100 % by coupling
PKC isoforms. Moreover, PMA-induced potentiation
was fully inhibited when εV1-2 (100 μM) was present in
the media indicating that nPKCε seems to play an
important role in the PKC coupling to ACh release
enhancement induced by PMA. A similar role of nPKCε
has been described above in high Ca2+ and in
stimulation-induced synaptic activity conditions. There-
fore, next, we investigate whether the effects of blocking
nPKCε translocation in both PMA-induced and
electrical stimulation-induced PKC coupling to ACh re-
lease are in any way similar or related. We performed a
pretreatment with εV1-2 (1 μM, 10 μM and 100 μM, 1 h
of incubation) before a second incubation with PMA (10
nM, an additional hour) under basal conditions. Then,
we repeated these experiments with coincident electrical
stimulation at 1 Hz. In basal conditions, PMA did not
exert its full effect when εV1-2 was present at 10 μM,
but the phorbol ester-induced increase in transmitter re-
lease is completely occluded after pretreatment with
100 μM εV1-2 (1 h of incubation) (Fig. 2c). Interestingly,
however, the result (a full abolition of PMA potentiation)
was the same when εV1-2 was present only at 10 μM
but coincides with electrical stimulation at 1Hz. Thus,
the tonic coupling of PKC to maintain ACh release dur-
ing activity (maintenance effect) and the PMA-induced
coupling that results in ACh release potentiation
(potentiation effect) share a common nPKCε-based link.
nPKCε and PKA activity
Some dependence of PKC on PKA activity in the fine
control of neuromuscular synaptic functionalism and
ACh release has also been shown [11]. Thus, the quantal
content was reduced after CaC incubation (indicating
the coupling of PKC to the maintenance or potentiation
of ACh release) when neurotransmission was previously
enhanced by PKA stimulation with Sp-8-BrcAMP [10];
see also Fig. 3 seventh column). Figure 3 gathers
together some newly reproduced data of previously pub-
lished results [10, 11] to facilitate comparisons with and
the interpretation of the results shown in the last part of
the figure. PKA inhibition in basal conditions (N-[2-((p-
Bromocinnamyl)amino)ethyl]-5-isoquinolinesulfona-
mide, 2HCl -H-89-, 5 μM) reduces ACh release whereas
stimulation (Sp-8-BrcAMPs, 10 μM) increases it. Thus,
unlike PKC, PKA can be tonically active in release main-
tenance in basal conditions. Figure 3 also shows that
PKA was able to modulate ACh release independently of
PKC activity because once PKC activity had been en-
hanced by PMA, further stimulation or inhibition of
PKA increased or decreased ACh release normally.
However, once PKA had been inhibited or stimulated,
PMA did not increase ACh release. It seems, then, that
PKA stimulation caused PKC coupling to release, so
PKC could not be further pharmacologically stimulated
with PMA. This means that PKC may be reaching a
maximum level of activity depending of PKA. On the
other hand, PKA inhibition prevented PKC from being
stimulated and coupled to ACh output.
Next, we analyzed the involvement of the nPKCε iso-
form in this PKA-mediated PKC activity. The inhibitor
εV1-2 was added in order to block nPKCε translocation
before PKA stimulation with Sp-8-BrcAMPs or inhib-
ition with H-89 (Fig. 3). Interestingly, PKA inhibition
with H-89 can reduce normal release. So PKA seems ac-
tive and its coupling to ACh release can be inhibited
normally by H-89 independently of nPKCε status. How-
ever, PKA stimulation with Sp-8-BrcAMPs cannot in-
crease ACh release after preincubation with εV1-2. It
seems that nPKCε translocation enables PKA to increase
its coupling to ACh release and potentiate it above a
basal constitutive coupling.
Activation and inhibition of PKA was also evaluated
before εV1-2 pre-incubation. When nPKCε translocation
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is blocked after PKA stimulation with Sp-8-BrcAMPs or
after inhibition with H-89, there is no change in ACh re-
lease, which suggests that nPKCε is not able to modulate
neurotransmission once the mechanism of release has
been activated or inhibited by the action of PKA. How-
ever, quantal content is reduced by CaC when neuro-
transmission is previously enhanced by PKA stimulation
with Sp-8-BrcAMP, which indicates the coupling of PKC
(isoforms other than nPKCε) to ACh release mainten-
ance or potentiation (seventh column in the Fig. 3).
In summary, at this point we define four conditions
that result in PKCs coupling to maintain or potentiate
ACh release and in which nPKCε plays a meaningful
role: i) continuous synaptic activity by electrical
stimulation, ii) high external Ca2+, iii) direct PKC
stimulation with PMA and iv) PKA stimulation with
Sp-8-BrcAMPs. These four conditions involve high
ACh release by increased quantal content (in the
cases of high Ca2+, PMA and Sp-8-BrcAMPs) or
merely by repeated ACh secretion events in electrical
stimulation. When nPKCε is blocked with the peptide
εV1-2, the PKC coupling to ACh release (which can
be seen by using CaC) cannot be demonstrated in
electrical stimulation and high Ca2+ conditions and
the ACh release potentiation does not occur in PKC
stimulation with PMA and PKA stimulation with Sp-
8-BrcAMPs.
nPKCε and the mAChR signaling pathway
It is known that presynaptic mAChRs can control PKC
activity. Figure 4 includes some newly reproduced data
of previously published results [10, 16] so that compari-
sons with the results involving nPKCε can be made. The
figure shows the effect on ACh release of the M1
mAChR-subtype blocker pirenzepine (PIR), the M2
blocker methoctramine (MET) and the panmuscarinic
blocker atropine (AT). The use of these inhibitors shows
that M1-type potentiates release whereas M2-type re-
duces release in the adult NMJ. Moreover, when the
M1/M2 mechanism is fully blocked with the unselective
inhibitor AT, ACh release is potentiated which indicates
a predominance of the M2 mechanism in resting condi-
tions. The figure also shows that after blocking the
muscarinic mechanism with AT – but also the M1
mechanism with PIR or the M2 mechanism with MET,
thus producing an M1/M2 imbalance – PKCs become
coupled to potentiate ACh release. This coupling was
assessed by the reduction of release produced by CaC in
these circumstances. Therefore, we studied the possible
involvement of nPKCε in this mAChR-linked PKC coup-
ling to ACh release. The inhibitor εV1-2 was added to
block nPKCε translocation after or before a preincuba-
tion (1 h) with the M1 blocker PIR, the M2 blocker
MET or the panmuscarinic blocker atropine AT. Figure 4
shows that the peptide makes no change when it is
Fig. 3 nPKCε and PKA activity in diaphragm muscles. Changes in ACh release after PKA stimulation (Sp-8-BrcAMPs, 10 μM) and PKA inhibition
(H-89, 5 μM). Moreover, Sp-8-BrcAMPs and H-89 were incubated before and after PMA (10 nM) and εV1-2 incubation (10 μM). Seventh column
shows the effect of CaC (10 μM) after a preincubation with Sp-8-BrcAMPs * p < 0.05 vs. the corresponding control
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incubated after the blockers of mAChRs, which suggests
that nPKCε translocation is not an important step in
controlling release after mAChR modulation has been
established. In reciprocal experiments, we evaluated the
well known effect of muscarinic drugs after a εV1-2 pre-
incubation. The figure shows that after an initial incuba-
tion with εV1-2 (1 h), a second incubation with AT, PIR
or MET produces no change in EPP size. This indicates
that (as what happens in high Ca2+ media, continuous
electrical activity, PMA incubation and Sp-8-BrcAMPs
incubation) once drug-induced muscarinic modulation
has been produced on release, it is not affected if nPKCε
is blocked but can be prevented by previous nPKCε
translocation block. This emphasizes the importance of
nPKCε allowing transmitter release control.
nPKCε and the purinergic signaling pathway
It seems that one of the major roles of adenosine recep-
tors (AR) is to control synaptic depression. Synaptic de-
pression during imposed synaptic activity (40Hz for
2 min of supramaximal stimuli reduce the EPP size by
about 50 %, see Fig. 5a) is lessen by adding adenosine
(Adenosine 5′-triphosphate disodium salt hydrate –
ADO-, Fig. 5b) but increased by blocking AR with 8-(p-
Sulfophenyl) theophylline hydrate (8SPT) (see [20, 21,
25]). We investigated the possible involvement of nPKCε
in modulating synaptic depression during repetitive ac-
tivity. We observed no difference in the size of the last
EPPs in the presence and absence of the peptide εV1-2
(Fig. 5c). This suggests that the εV1-2 has no effect by it-
self on the normally produced activity-induced depression
of the EPPs. Interestingly, however, in the presence of
εV1-2, added ADO can not protect against depression
(Fig. 5d). In the presence of εV1-2, AR are still tonically
involved in the control of depression because the EPP size
decreases as normal when receptors are blocked by 8SPT
as occurs in the absence of the peptide (data not shown).
These results suggest that nPKCε has a role in the puri-
nergic mechanism of depression control. Whereas the
tonic coupling of AR in the control of depression seems
to be nPKCε independent, the kinase seems to be neces-
sary if AR is to be additionally stimulated with ADO. The
previous nPKCε translocation block using the peptide
εV1-2 leads to the PKC uncoupling from ACh release in
several conditions and also to the exogenous ADO being
unable to protect against EPP depression.
Discussion
Several PKC isoforms have been described in the pre-
synaptic component of the NMJ [12, 33–39]: classical
isoforms PKCα and PKCβI and the novel isoforms PKCθ
and PKCε [12, 29]. Experiments on PKCθ knockout
mice [39, 40] and PKCε block [29] suggest that these
isoforms have a role in transmitter release. The main re-
sult of the present study is the observation that the
nPKCε isoform helps to modulate transmitter release at
the NMJ. Using the specific nPKCε translocation inhibi-
tor peptide εV1-2 in electrophysiological experiments,
we observed that the nPKCε was clearly involved in sev-
eral conditions with the common denominator of PKC
coupling to maintain or potentiate ACh release in the
NMJ: i) low frequency electrical stimulation-induced
Fig. 4 nPKCε and the mAChR signaling pathway in diaphragm muscles. Histogram shows changes in ACh release in the presence of mAChR
blockers (PIR, 10 μM; MET, 1 μM; AT, 2 μM). We evaluated its effects in basal conditions and after a second incubation with CaC (2: CaC) or εV1-2
(2: εV1-2). We also preincubated with εV1-2 (1: εV1-2) and then blocked mAChR. * p < 0.05 vs. the corresponding control
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activity, ii) high external Ca2+ and inflow, iii) PKA stimu-
lation with Sp-8-BrcAMPs, iv) stimulation with phorbol
ester and v) interference with mAChR-mediated presynap-
tic modulation of ACh release. In addition, we observed
that nPKCε was involved in the AR control of synaptic
depression.
The translocation inhibitor peptide εV1-2 has been
used as a nonpharmacological tool in many studies with
promising results. It interferes in the nPKCε interaction
with the specific anchoring protein εRACK and, there-
fore, inhibits the anchoring of nPKCε near its substrates
and prevents any subsequent substrate phosphorylation
Fig. 5 nPKCε and adenosine receptors in diaphragm muscles. We produced nerve-delivered stimulation (40 Hz, 2 min of supramaximal stimuli)
and analyzed the effect of adenosine (ADO, 10 μM) and the peptide εV1-2 (10 μM) on modulating synaptic depression. We compared the mean
size of the first 15 EPPs of each train and the mean size of the last 15 EPPs. The figure shows representative raw data. Horizontal bars: 50 ms. Vertical
bars: 10 mV. a Effect of nerve-delivered stimulation (40 Hz, 2 min of supramaximal stimuli) and the normally occurring synaptic depression of the last
EPPs in the train. b Effects of ADO in synaptic depression during imposed synaptic activity. c Effect of the peptide εV1-2. d Shows that, in the presence
of εV1-2, added ADO cannot protect against depression
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and activity [1]. εV1-2 does not interfere with classic
calcium-dependent cPKCs not even with nPKCδ [1, 41–43].
Evidence also shows that the effects found using the
nPKCε-specific translocation inhibitor peptide are con-
firmed when nPKCε knockout mice are used [44, 45]. In
our experiments the effect of εV1-2 (100 μM) was studied
in parallel to the effect of the scrambled version of this
peptide (εV1-2-s, 100 μM). No effect of the inactive form
was found. We also performed Western blot analysis to
prove that the inhibitor peptide significantly decreases
nPKCε levels in the synaptic membrane, which indicates
that its translocation has been blocked. Furthermore, εV1-
2 significantly also decreases pnPKCε levels in the synaptic
membrane indicating a less amount of active nPKCε
(pnPKCε) and, therefore, a decrease in the catalytical ac-
tion of the nPKCε. We assayed εV1-2 concentrations of
1–100 μM. The range of values has been widely reported
in the literature [45–50].
PKC coupling to transmitter release
Now let us turn to the role of serine kinases in synaptic
function. In resting neuromuscular preparations, PKA
couples constitutively to ACh release [11]. However, al-
though PKC can be stimulated pharmacologically with
such phorbol esters as PMA to potentiate ACh release,
PKC is uncoupled in basal conditions because quantal
content does not change when all PKC isoforms are
inhibited with the pan-inhibitor CaC [9–11]. However,
taking CaC modification of the ACh release as a test,
there are several experimental situations in which PKC
isoforms play a regulated role in release modulation. In
these situations, ACh release is increased and CaC re-
duces this release potentiation (which indicates that
PKC is coupled to ACh release) [9–11, 51]. Quantal con-
tent is reduced by CaC incubation during continuous
electrical stimulation at 1Hz [12], in the presence of high
external Ca2+ [9], after PKA stimulation with Sp-8-
BrcAMP (as example of intracellular pathways modifica-
tion [11]) and after mAChR block [10, 51]. When nPKCε
translocation is blocked with the peptide εV1-2, the PKC
coupling to ACh release (evidenced by CaC incubation)
cannot be demonstrated in electrical stimulation and
high Ca2+ conditions and ACh release potentiation does
not occur in PKA stimulation with Sp-8-BrcAMPs or in
mAChR block. Likewise, after nPKCε translocation
block, PKCs cannot be stimulated with PMA and
exogenous adenosine cannot work against repetitive
activity-induced depression. This isoform, then, may be
involved in the presynaptic function of maintaining and
potentiating transmitter release, probably by controlling
the coupling of other PKC isoforms to the ACh release.
Interestingly, in all cases, the nPKCε translocation to
the membrane needs to be blocked some time before
(typically the preincubation with εV1-2 takes 1 h) the
onset of the changes in the conditions that lead to PKC
coupling. It seems that once the nPKCε translocation to
the membrane has been triggered by, for instance, phor-
bol ester stimulation, 1 Hz trains or muscarinic signaling
collapse with AT, the PKC isoform activation makes the
synapse potentiation-competent for some time, such that
subsequent incubation with εV1-2 produces no effect. A
long-lasting permanence of phosphorylated nPKCε in
the membrane, the permanence of the phosphorylated
PKC substrates or a cascade of events initiated during
the initial kinase activation may produce this potenti-
ation competent state. Recent studies have demonstrated
that PKC phosphorylates several molecules of synaptic
vesicle exocytic apparatus and there is evidence that
these PKC-mediated phosphorylations contribute dir-
ectly to the regulation of the neurotransmitter release
[52–54]. These proteins may be the link between the
ACh release machinery and nPKCε.
When nPKCε translocation is blocked after PKC has
coupled to ACh release (in all the experimental condi-
tions studied here), there is no change in ACh release,
which indicates that nPKCε is not able to modulate
neurotransmission once the release mechanism has been
activated. However, quantal content is reduced by CaC
in the same conditions, which indicates that other PKC
isoforms may continue the initial permissive effect of
nPKCε on release potentiation.
Therefore, although the specific role of nPKCε in ACh
release is not known, here we show that it is involved in
a crucial step in the release process. The individual ana-
lysis of each condition may provide additional insight
into particular aspects of nPKCε involvement. Figure 6
is a graphic representation of the main observations of
this study, showing that the blockade of nPKCε trans-
location, and therefore its activity, impedes the regulated
coupling of PKC to ACh release potentiation.
nPKCε and electrical stimulation
Blocking nPKCε translocation prevents electrical stimu-
lation from coupling PKCs to ACh release. However,
electrical stimulation by itself (at 1 Hz) does not change
quantal content [12] and the present results show that
neither does blocking the nPKCε translocation by itself.
Thus, the CaC-inhibitable and nPKCε translocation-
dependent PKC coupling to ACh release during elec-
trical stimulation and continuous activity may be
involved in some maintenance (or sustainability) func-
tion but not in direct ACh release potentiation. How-
ever, the tonic maintenance effect of the PKC coupling
and the PMA-induced coupling, which result in release
potentiation, share a common nPKCε link because the
PMA effect is fully prevented with a lower concentration
of εV1-2 if it coincides with electrical stimulation.
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nPKCε and Ca2+ions
Blocking the epsilon isoform prevents PKC coupling in
high Ca2+ concentration, which helps to potentiate re-
lease. Thus, also in this case, nPKCε translocation and
PKC coupling to ACh release seems to be closely re-
lated. Because nPKCε is a Ca2+-independent isoform,
nPKCε would be activated and coupled to ACh release
by diacylglycerol in the context of the exocytotic process
started by Ca2+ entry.
nPKCε and PKA stimulation
PKA stimulation with Sp-8-BrcAMP results in
Ca2+-dependent increased ACh release and a parallel
CaC-inhibitable PKC coupling [10, 11]. Preincubation
with εV1-2 prevents Sp-8-BrcAMP release potenti-
ation. This indicates that at least some of the PKA-
mediated potentiation of release may be produced by
the involvement of nPKCε. As shown here, blocking
PKCε with the specific blocker εV1-2 does not prevent
the inhibitory effect of H-89, which indicates that PKA
is tonically active and, therefore, that PKA can modu-
late transmitter release to a certain level independently
of nPKCε status. Interestingly, however, after εV1-2
incubation, PKA cannot be stimulated with Sp-8-BrcAMPs.
Thus, nPKCε translocation inhibition may be enough to
prevent PKA from functioning above its basal tonic activity.
nPKCε and the PMA stimulation of PKC
All PKC isoforms can be stimulated pharmacologically
by phorbol esters such as PMA, which also increase
ACh release and need Ca2+ ions [9]. However, CaC can-
not revert the PMA effect to the initial point, although it
can be suppressed by preincubation with CaC. This shows
that PMA and CaC are powerful positive and negative ir-
reversible pharmacological regulators of PKC activity.
We investigate how blocking nPKCε translocation af-
fects the PMA effect. PMA cannot enhance ACh release
when εV1-2 is present at high concentration (100 μM)
or when εV1-2 is present only at 10 μM but coincides
with electrical stimulation at 1Hz. Thus, the effect of
PMA on neurotransmission is largely dependent on
nPKCε, and the PMA and electrical activity mechanisms
partially share a common pathway.
In previous studies we identified several conditions
that hamper or prevent the PMA-induced stimulation of
PKC coupling to potentiate ACh release just as happens
with εV1-2 preincubation. What do these conditions
have in common that can shed some light on the role of
nPKCε? PMA cannot stimulate release after blocking
(H-89) or stimulating (Sp-8-BrcAMP) PKA and after re-
ducing (5 mM Mg2+, μ-Agatoxin) or increasing (5 mM
Ca2+) Ca2+ inflow [11]. After PKA is stimulated or Ca2+
inflow increased, PKCs are active and coupled to release
potentiation. We believe that the PKC pathway may be
saturated almost to full capacity (in relation to ACh re-
lease) so it would not be additionally activated by PMA.
On the contrary, after PKA is blocked or Ca2+ inflow re-
duced, PKCs are inactive and uncoupled to release so
the pathway may be inactive or blocked. Thus, with re-
spect to the well known phorbol ester effect, it seems
that blocking nPKCε translocation mimics blocking PKA
activity or reducing Ca2+ inflow. These data reinforce
the notion that there is a close relation between nPKCε,
PKA and Ca2+ ions in the promotion of ACh release and
strongly suggest that nPKCε plays a central role in trans-
mitter release.
Fig. 6 Graphic representation of the central role of nPKCε activity in the regulated coupling of PKC to ACh release potentiation. The diagram
illustrates several conditions that are known to couple PKC to enhance ACh release in the NMJ: electrical stimulation (1 Hz), high Ca2+ inflow,
stimulation with phorbol ester (PMA), PKA stimulation with Sp-8-BrcAMP, and the interference with presynaptic mAChR (with atropine –AT–) and
AR (with adenosine –ADO–). In all these conditions, preincubation with the specific nPKCε translocation inhibitor peptide εV1-2 impairs the PKC
coupling and highlights the nPKCε isoform role in the modulation of ACh release in this synapse
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Interestingly, some experimental conditions prevent
the PMA effect while others allow it. PMA is able to in-
crease ACh release during or after electrical stimulation
or when the mAChRs are blocked [10]. This suggests
that in these two conditions other PKC isoforms may
also be involved in ACh release (see later).
Altogether the results suggest that the translocation of
PKCε to the membrane is necessary if PKC family is to
be involved in ACh release in the NMJ. In turn, this
suggests that this isoform plays a key permissive role
that may allow other PKCs to have a positive effect on
ACh release. It seems that nPKCε is key to (and may be
causally involved in) the high ACh release situations
described here: namely, high Ca2+ entry, continuous syn-
aptic activity, PKA stimulation and phorbol ester stimu-
lation of PKCs.
nPKCε and the mAChR pathway
In the presynaptic membrane, mAChRs are an import-
ant self-control mechanism of ACh release [10, 15–18,
55–57]. In the NMJ, the intracellular coupling of the
PKC pathway can mediate the mAChR modulation of
ACh release at least in part [10]. Specifically, blocking
the muscarinic mechanism results in a CaC-inhibitable
PKC coupling and ACh release potentiation. Thus, PKC
become coupled on mAChR signaling inhibition. We
found here that after an initial incubation with εV1-2, a
second incubation with AT, PIR or MET produces no
change in EPP size or quantal content. These data
suggest that, in basal conditions, mAChRs reduce PKC
activity and ACh release. Impairing the muscarinic func-
tion results in PKC coupling and increased release, in
which nPKCε seems to play an important role. Thus, the
muscarinic modulation of release can be prevented by
PKCε translocation block.
Interestingly, as stated in the section above, PMA can
increase ACh release after the action of the blockers
(AT, PIR, MET). Thus, the effects of AT and PMA seems
to be additive. The PKC isoforms activated by the use of
AT are probably not all isoforms and this allows PMA to
complete the activation of the remaining isoforms and
the same may occur with the electrical stimulation and
PMA effects that are also additive as previously stated.
Thus, nPKCε could be involved in activity- and muscarinic-
dependent mechanisms of release modulation together with
other PKC isoforms.
nPKCε and adenosine receptors signaling
Exogenous added ADO reduces synaptic depression at a
moderate level of imposed activity (40Hz) on the NMJ.
At high levels of activity (100Hz), endogenous ADO pro-
duction in the synaptic cleft can be sufficient to interact with
A1R receptors to protect against depression [20, 21, 25].
Here we found that in the presence of εV1-2, added ADO
is not able to protect against depression. If nPKCε is an
important element in the adenosine-mediated mechanism
of depression control because it increases the quantal con-
tent of the last EPPs in a train (the coupling of PKCs in
the adult NMJ potentiates ACh release), the nPKCε trans-
location inhibitor peptide εV1-2 must prevent the protect-
ive effect on depression of ADO, as we found here.
Conclusion
In summary, by blocking nPKCε translocation to the
membrane in electrophysiological experiments, we show
a clear involvement of this PKC isoform in several con-
ditions with the common denominator of PKC coupling
to maintain or potentiate ACh release in the NMJ. These
conditions are: electrical stimulation, high Ca2+ in-
flow, stimulation with phorbol ester, PKA stimulation,
and interference with presynaptic mAChR and AR. In
all these conditions, preincubation with the specific
nPKCε translocation inhibitor peptide εV1-2 impairs
PKC isoforms coupling to ACh release and points to
the nPKCε isoform as a key element in the modula-
tion of ACh release in this synapse. These results are
represented in Fig. 6.
Methods
Animals
Diaphragm muscles of young adult male Sprague–Daw-
ley rats (30–40 days; Criffa, Barcelona, Spain) were used
to perform stimulation experiments, Western blotting
and electrophysiological experiments. Diaphragm and
LAL muscles were used to perform immunohistochem-
istry. The animals were cared for in accordance with the
guidelines of the European Community Council Direct-
ive for the humane treatment of laboratory animals. This
study was approved by the Ethics Committee of the
Rovira i Virgili University (Ref. number 233).
Antibodies
The primary antibodies used for Western blot and im-
munohistochemistry analysis were obtained from the
following sources: rabbit anti-PKCε and goat anti-
phospho-PKCε (Ser729) polyclonal antibodies from
Santa Cruz Biotechnology (Santa Cruz, CA); rabbit anti-
PKCε and rabbit anti-phospho-PKCε (Ser729) polyclonal
antibodies from Upstate Biotechnology (Millipore, Lake
Place NY); goat anti-GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) from Imgenex (San Diego, CA) and rabbit
anti-pan-actin polyclonal antibody from Cell Signaling
Technology, Inc (Beverly, MA). The secondary antibodies
used in the Western blot were donkey anti-rabbit conju-
gated to HRP (Horseradish Peroxidase) from Jackson
Immunoresearch and rabbit anti-goat HRP from Molecular
Probes (Eugene, OR). For the immunohistochemistry we
also used antibodies that are commonly used as markers to
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differentially detect the parts of the NMJ (syntaxin and
S100): mouse monoclonal and rabbit polyclonal anti-
syntaxin antibodies (Sigma, St Louis, MO); rabbit anti-S100
antibody (Dako, Carpinteria, CA) and mouse anti-S100
antibody (Acris, Germany). The secondary antibodies used
were donkey anti-rabbit or donkey anti-mouse conjugated
to Alexa Fluor 488 and Alexa Fluor 647 from Molecular
Probes (Eugene, OR). Postsynaptic acetylcholine receptors
(AChRs) were detected with α-bungarotoxin (α-BTX) con-
jugated to tetramethyl rhodamine iso-thiocyanate (TRITC)
from Molecular Probes (Eugene, OR).
As a control, the primary antibodies were omitted
from some muscles during the immunohistochemical
and Western blot procedures. None of these control
muscles exhibited positive staining or revealed bands of
the appropriate molecular weight with the respective
procedures. In double-staining protocols, omitting either
one of the two primary antibodies completely abolished
the corresponding staining and there was no cross-
reaction with the other primary antibody. Pretreatment
of a primary antibody with an excess of the appropriate
blocking peptide (between three- and eightfold by
weight) in skeletal muscle tissue prevented immunola-
beling. All the primary antibodies detected a single band
with the referenced molecular weight on Western blot
(manufacturer’s data sheets; [29]).
Reagents
For the different treatments we used substances that
modulate ACh release involving PKC activity.
nPKCε-specific translocation inhibitor peptide
εV1-2, nPKCε-specific translocation inhibitor peptide
(myristoylated PKC-ε V1-2 peptide, EAVSLKPT) from
Calbiochem (Merk, Germany) was made up as 1 mM in
distilled water or normal Ringer solution. Working solu-
tions were 1, 10 and 100 μM. As a negative control of
the nPKCε-specific translocation inhibitor peptide we
used scrambled εV1-2 peptide (εV1-2-s, LSETKPAV),
containing the same aminoacids as the inhibitor peptide
but in a different sequence, from Calbiochem (Merk,
Germany). In no case does εV1-2-s have an effect.
Drugs that modulate PKC activity
Phorbol 12-myristate 13-acetate (PMA, Sigma) was
made up as a 10 mM stock solution in dimethylsulfoxide
(DMSO, Tocris, Ellisville, MO, USA). Calphostin C
(CaC, Sigma) was made up as a 2.5 mM stock solution
in DMSO. Working solutions were PMA, 10nM and
CaC, 10 μM.
Calcium, magnesium and P/Q-type calcium channel blocker
In some experiments, we increased the content of cal-
cium or magnesium in the bath to 5 mM. The P/Q-type
calcium channel blocker, the toxin ω-Agatoxin IVA (ω-
Aga-IVA), was purchased from Research Biochemicals
Inc. Controls and toxin-treated muscles were assayed in
the presence of 0.01 % bovine serum albumin (BSA)
(Sigma, St. Louis, MO, USA). Working solutions of ω-
Aga-IVA are 100 nM.
Muscarinic agents
Stock solutions: Pirenzepine dihydrochloride 10 mM
(PIR, Tocris), Methoctramine tetrahydrochloride 1 mM
(MET, Sigma) and Atropine 200 μM (AT, Sigma). Work-
ing solutions: PIR 10 μM, MET 1 μM, and AT 2 μM.
Drugs that modulate PKA activity
N-[2-((p-Bromocinnamyl)amino)ethyl]-5-isoquinoline-
sulfonamide, 2HCl (H-89, Calbiochem) was made up as
a 5 mM stock solution in DMSO. Adenosine 3′,5′-cyclic
Monophosphorothioate, 8-Bromo-, Rp-Isomer, Sodium
Salt (Sp-8-BrcAMPs, Calbiochem) was made up as a
5 mM stock solution in deionized water. Working solu-
tions were Sp-8-BrcAMPs 10 μM and H-89 5 μM.
Nonselective AR agonist
The stock solution of Adenosine 5′-triphosphate diso-
dium salt hydrate (ADO, Sigma-Aldrich) was made up
as a 100 mM solution in deionized water. The working
solution was 10 μM.
All stock solutions were stored at −20 °C for less than
four weeks. We chose drug concentrations that did not
change the size of the MEPPs in the concentration-
response curves performed in previous experiments. The
final DMSO concentration in control and drug-treated
preparations was 0.1 % (v/v). In control experiments,
this concentration of DMSO did not affect any of the
parameters studied (data not shown).
Stimulation of the muscle and incubations with reagents
In all the experimental protocols, the diaphragm muscle
from young adult rats were excised together with the
phrenic nerve and placed in oxygenated Ringer solution
(see below) continuously bubbled with 95 % O2 / 5 %
CO2 at room temperature. To stimulate the muscle, the
phrenic nerve was stimulated at 1 Hz by an A-M
Systems 2100 isolated pulse generator (A-M System,
Carlsborg, WA). Muscle contraction was abolished by
using μ-conotoxin GIIIB (μ-CgTx-GIIIB, 3 μM −1.5 μM,
from ICS, International Clinical Service GmbH,
München).
Consecutive incubations with two substances are used
as a pharmacological tool to investigate the possible oc-
clusive or additive crosstalk effects between them. We
recorded and measured control EPPs, and then incu-
bated the muscle for one hour in the first compound.
After recording the EPPs again, we incubated it for one
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hour in the second compound (in the presence of the
first drug) and then recorded the EPPs.
Western blot analysis
Diaphragm muscles from adult rat were dissected, fro-
zen in liquid nitrogen, and stored at −80 °C before use.
The muscles were homogenized using a high-speed
homogenizer (overhead stirrer, VWR International,
Clarksburg, MD) in lysis buffer containing 150 mM
NaCl, 20 mM Tris–HCl, pH 7.5, 2 mM EGTA (Ethylene
Glycol Tetraacetic Acid), and 5 mM EDTA (Ethylenedi-
nitrilo-tetraacetic acid) supplemented with 1 % Triton
X-100, 1 mM PMSF (phenylmethanesulfonyl fluoride),
50 mM NaF, and 1 mM sodium orthovanadate from
Sigma, (St. Louis, MO) and protease inhibitor cocktail
(Sigma-Aldrich Corp., Saint Louis, MO, USA). Insoluble
material was removed by centrifugation at 1000 g for
10 min. The supernatants were collected and centrifuged
at 15000 g for 20 min. Finally, the resulting supernatants
(total protein lysates) were collected. Protein concentra-
tions were determined by using the Bio-Rad DC protein
assay (Bio-Rad, Hercules, CA). Experimental procedures
were performed to determine the linear and quantitative
dynamic range for each target protein and the appropri-
ate dilutions of samples were used for accurate and nor-
malized quantitation by means of densitometric analysis.
Protein samples of 15 or 30 μg were separated by 8 %
SDS-polyacrylamide electrophoresis and electrotrans-
ferred to polyvinylidene difluoride (PVDF) membranes
(HybondTM-P; Amersham, GE Healthcare). The mem-
branes were blocked in Tris-buffered saline-0.1 %
Tween-20 (TBS-T) containing 5 % (W/V) nonfat dry
milk or in a blocking reagent to preserve phosphopro-
tein antigens (PhosphoBLOCKER™; Cell Biolabs, Inc.)
and probed with the primary antibody overnight at 4 °C.
The membranes were then incubated with the secondary
antibody and visualized the enhanced chemilumines-
cence with the ECL kit (Amersham Life Science, Arling-
ton Heights, IL).
In diaphragm muscles, the synaptic membranes were
obtained. Synaptic and extrasynaptic parts of the dia-
phragm muscle were separated as previously described
[12]. We performed control experiments to check that
our protocol for dividing the diaphragm muscle into
synaptic and extrasynaptic region was accurate. In some
muscles, we repeated the process of separation and de-
tected NMJs with TRITC-conjugated α-BTX. We also
stained the nerves with an antibody against anti-
neurofilament-200 and did not detect any nerves in
extrasynaptic regions. The muscles were homogenized
using a high-speed homogenizer (overhead stirrer, VWR
International, Clarksburg, MD) in lysis buffer (see above)
and the insoluble material was removed in the same way
(by centrifugation at 1000 g for 10 min) but this time
the resulting supernatant was collected and centrifuged
at 130000 g for 1 h. The supernatant was the cytosolic
fraction, and the pellet was the membrane fraction. To as-
sess the separation of the membrane fraction from the
cytosol, we used a goat antibody directed against GAPDH,
a protein specific to the cytosolic fraction. GADPH immu-
noreactivity was not observed in any case in the mem-
brane fraction. The samples were processed the same way
as another sample of total protein (see below).
The blots were visualized with a VersaDoc 3000
(Bio-Rad, Hercules, CA). The densitometry of the bands
was analyzed with the MetaMorph software. The inte-
grated optical density of the bands was normalized by
actin protein and to the background values. Also, as an-
other loading control, we used a total protein analysis
(Sypro Ruby protein blot Stain, Bio Rad) to measure the
total protein transferred on PVDF membranes. In all
cases, the quantitative results obtained by using actin or
total protein analysis were no different. The relative varia-
tions between the bands in the experimental samples and
the control samples were calculated from the same image.
The data were taken from densitometry measurements
made in at least five separate experiments, plotted against
controls. Data are mean values ± SD. Differences between
groups were tested using the t Student test or U test
(Mann–Whitney), and the normality of the distributions
was tested with the Kolmogorov-Smirnov test. The criter-
ion for statistical significance was p < 0.05 versus the
control.
Immunohistochemistry and confocal microscopy
Whole muscle mounts were processed by immunohisto-
chemistry to detect the localization of the nPKCε iso-
form at the NMJ. LAL and diaphragm muscles were
used to perform the immunohistochemistry technique.
Muscles from young adult rats were fixed with 4 % para-
formaldehyde for 30 min. After fixation, the muscles
were rinsed with PBS and incubated in 0.1 M glycine in
PBS. The muscles were permeabilized with 0.5 % Triton
X-100 in PBS, and nonspecific binding was blocked with
4 % bovine serum albumin (BSA). Then, muscles were
incubated overnight at 4 °C in mixtures of three primary
antibodies raised in different species (anti-nPKCε iso-
form antibody and anti-syntaxin or anti-S100) and
rinsed. The muscles were then incubated for four hours
at room temperature in a mixture of secondary anti-
bodies. The AChRs were detected with α-BTX conju-
gated with TRITC. At least three muscles were used as
negative controls as described above. For a better analysis
of the localization of the nPKCε isoform at the NMJ, mus-
cles were processed to obtain semithin cross-sections
from whole-mount multiple-immunofluorescent stained
muscles. This method provided a simple and sensitive
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procedure for analyzing the cellular distribution of mole-
cules at the NMJ [32].
Labeled NMJs from the whole-mount muscles and the
semithin cross-sections were viewed with a laser-scanning
confocal microscope (Nikon TE2000-E). Special consider-
ation was given to the possible contamination of one
channel by another. In experiments involving negative
controls, the photomultiplier tube gains and black levels
were identical to those used for a labeled preparation
made in parallel with the control preparations. There were
no differences in nPKCε immunolocalization between dia-
phragm and LAL muscles. Since better NMJ images can
be obtained from LAL, we decided to perform a wider
study on this muscle. At least 25 endplates per LAL
muscle were observed, and at least six muscles were stud-
ied. Images were assembled using Adobe PhotoShop soft-
ware (Adobe Systems, San Jose, CA) and neither the
contrast nor the brightness was modified.
Electrophysiology
Diaphragm muscles from adult rats and their nerve
supply were surgically removed and pinned in a Sylgard-
lined 35-mm Petri dish containing normal Ringer solu-
tion (in mM) – NaCl 135, KCl 5, CaCl2 2.5, MgSO4 1,
NaH2PO4 1, NaHCO3 15, glucose 11 – and bubbled
continuously with 95 % O2, 5 % CO2, which flowed into
the Petri dish to superfuse the muscle preparation. The
overflow was evacuated by suction. The solution was not
bubbled directly in the Petri dish to minimize vibration
during electrophysiological recording. Temperature and
humidity were set to 26 °C and 50 %, respectively. The
bath temperature was monitored during the experiments
(23.4 °C ± 1.7, Digital Thermometer TMP 812, Letica,
Barcelona, Spain). Intracellular recordings (EPPs and
MEPPs) were performed with conventional glass micro-
electrodes filled with 3 M KCl (resistance: 20–40 MΩ).
Recording electrodes were connected to an amplifier
(Tecktronics, AMS02, Oregon, USA), and a distant Ag-
AgCl electrode connected to the bath solution via an
agar bridge (agar 3.5 % in 137 mM NaCl) was used as
reference. The signals were digitized (DIGIDATA 1322A
Interface, Axon Instruments Inc., Weatherford, TX,
USA), stored and computer-analyzed. The software
Axoscope 9.0 (Axon Instruments Inc.) was used for data
acquisition.
To prevent muscle contraction during EPP recordings,
we used μ-CgTx-GIIIB(1.5 μM) with a recirculation
system. After a muscle fiber had been impaled, the nerve
was continuously stimulated (70 stimuli at 0.5Hz) using
two platinum electrodes coupled to a pulse generator
(CIBERTEC CS-20) and linked to a stimulus isolation
unit. We recorded the last 50 EPPs. We selected fibers
with membrane potentials of no less than -70 mV and
used only those results from preparations which did not
deviate by more than 5 mV during the recording. The
mean amplitude (mV) per fiber was calculated and
corrected for non-linear summation (EPPs were usually
more than 4 mV) [58] assuming a membrane potential
of – 80 mV. Quantal content (M) was estimated by the
direct method, which consists of recording MEPPs and
EPPs simultaneously and then calculating the ratio: M =
Average Peak EPP/Average Peak MEPP. Incubation with
the drugs took place for one hour. We studied a mini-
mum of 15 fibers per muscle and usually a minimum of
5 muscles in each type of experiment.
We also applied repetitive stimulation (trains at 40 Hz
for 2 min) to evaluate the effects of the peptide εV1-2
and reagents affecting adenosine receptors on synaptic
depression. There were 10-min intervals between trains
to allow for muscle recovery. We recorded 2 min of
EPPS and used the first 15 and the last 15 EPPS to
evaluate changes in depression. We evaluated the ratio
between the mean size of the last 15 EPPs of each train
and the mean size of the first 15 EPPs. We also analyzed
possible facilitation as the ratio between the sizes of the
second EPP and the first EPP in each train of 40Hz. We
studied between 8 and 10 fibers per muscle and usually
between 5 and 8 muscles in each type of experiment. In
the single-fiber experiments, the drugs were added to
the bathing solution and the EPPs were recorded every
15 min for 60 min.
Standard sharp-electrode intracellular recording tech-
niques were used to show that MEPP amplitudes and
postsynaptic resting membrane potentials were un-
affected and, therefore, that all the compounds used act
presynaptically in the present conditions. The MEPP
frequency in each solution was recorded for 100 s from
at least 15 different neuromuscular junctions and the
values were averaged. ACh in the synaptic cleft can in-
crease during trains of 40 Hz. This may modify the sen-
sitivity of the AChRs. Therefore, we evaluated the size of
the MEPPs during the trains and did not notice any
change with the drugs used. For example, the change in
the amplitude of MEPPs during trains of 40Hz in the
presence of 25 μM adenosine was 14.90 % ± 2.07 and for
8-SPT it was 2.41 % ± 4.65 (P < 0.05).
The statistical software SPSS© v17.0 was used to analyze
the results. Values are expressed as means ± SEM. The
values are expressed as “percentage of change”. This is de-
fined as: [final value / initial value] X 100. We used
Welch’s two-tailed t-test for unpaired values because our
variances were not equal. We prefer this test because it is
more conservative than the ordinary t-test. Differences
were considered significant at P < 0.05.
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